Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide plus alternate-day prednisolone maintenance after autologous stem cell transplant for multiple myeloma
ACTRN12611000597998Phase 2Recruiting
- Sponsor
- Malignant Haematology and Stem Cell Transplantation Service
- Start
- Dec 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide and prednisolone in multiple myeloma (MM), sponsored by Malignant Haematology and Stem Cell Transplantation Service. Primary endpoint: Change in depth of disease response. Started Dec 2010; status: recruiting.
02
Drugs
lenalidomideprednisolone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12611000597998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000597998.